MorphoSys News

MorphoSys (ETR:MOR) Shareholders Have Earned a 228% Return Over the Last Year

Yahoo FinanceMay 10 14:15

MorphoSys AG Announces Major Voting Rights Shift

TipRanksMay 8 23:27

MorphoSys AG Announces Major Voting Rights Changes

TipRanksMay 7 22:57

MorphoSys Announces Barclays PLC's Voting Rights Shift

TipRanksMay 3 23:27

MorphoSys AG Reports Shift in Major Holdings

TipRanksMay 2 23:27

Analysts' Opinions Are Mixed on These Technology Stocks: Morphosys (GB:0NDV), Thales (GB:0IW5) and Capgemini SE (GB:0HAZ)

TipRanksMay 1 17:13

European Equities Traded in the US as American Depositary Receipts Decline

European equities traded in the US as American depositary receipts fell Tuesday morning, down 0.5% to 1,373.3 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by food

MT NewswiresApr 30 23:11

Barclays PLC Acquires 10% Stake in MorphoSys AG

TipRanksApr 30 22:57

MorphoSys AG Navigates Takeover and Asset Sale

TipRanksApr 30 21:59

MorphoSys AG Set for Novartis Acquisition

TipRanksApr 30 05:00

MorphoSys Group AG Q1 2024 EPS €(9.27) Down From €(0.94) YoY; Revenue €27.5M Up From €24.3M YoY

MorphoSys Group AG Q1 2024 EPS €(9.27) Down From €(0.94) YoY; Revenue €27.5M Up From €24.3M YoY

BenzingaApr 30 04:14

MorphoSys AG: Due to Sale and Transfer of Tafasitamab, 2024 Fincl Guidance Published on Jan 30 Cannot Be Maintained and Therefore Was Revoked >MOR.FF

MorphoSys AG: Due to Sale and Transfer of Tafasitamab, 2024 Fincl Guidance Published on Jan 30 Cannot Be Maintained and Therefore Was Revoked >MOR.FF

Dow JonesApr 30 04:05

MorphoSys AG 1Q Rev EUR27.5M >MOR.FF

MorphoSys AG 1Q Rev EUR27.5M >MOR.FF

Dow JonesApr 30 04:03

MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer Drug, Pelabresib

MorphoSys AG (NASDAQ:MOR) is reportedly facing a burgeoning safety concern surrounding pelabresib, an experimental myelofibrosis treatment.Myelofibrosis is a type of blood cancer characterized by the

BenzingaApr 30 00:36

MorphoSys AG Announces Major Shareholder Update

TipRanksApr 29 22:57

Impacted by reports of drug safety issues, Morphosys (MOR.US) says the Novartis Pharmaceuticals (NVS.US) acquisition will continue as planned

The Zhitong Finance App learned that on Monday, the stock price of German biotech company Morphosys (MOR.US) fell due to a news report about its drugs or safety risks, but Morphosys said that Novartis Pharmaceuticals (NVS.US) is still expected to complete its acquisition in the first half of this year. Prior to Morphosys' statement, the professional website StatNews quoted two people familiar with the matter as reporting that the company is developing an experimental drug pelabresib to treat myelofibrosis (a rare type of blood cancer affecting bone marrow)

Zhitong FinanceApr 29 20:21

MorphoSys AG Reports First Quarter 2024 Financial Results

EQS-News: MorphoSys AG / Key word(s): Quarterly / Interim StatementMorphoSys AG Reports First Quarter 2024 Financial Results 29.04.2024 / 22:01 CET/CESTThe issuer is solely responsible for the content

MorphoSysApr 29 12:00

New Safety Risk for MorphoSys Drug Could Complicate Novartis Deal - STAT

A new safety risk related to Morphosys's (NASDAQ:MOR) pelabresib, an experimental treatment for myelofibrosis, could complicate the company's planned $3B sale to Novartis (NYSE:NVS).

Seeking AlphaApr 29 08:52

MorphoSys AG Announces Shift in Major Holdings

TipRanksApr 26 22:57

MorphoSys AG Sees Shift in Major Shareholders

TipRanksApr 26 00:00